Novartis said it has agreed to acquire Advanced Accelerator Applications for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood-cancer drug Gleevec.
from WSJ.com: US Business http://ift.tt/2gVGqaS
via IFTTT
No comments:
Post a Comment